TLC178 designated by US FDA as drug for rare paediatric disease in the treatment of Rhabdomyosarcoma

TLC178 designated by US FDA as drug for rare paediatric disease in the treatment of Rhabdomyosarcoma By Laxmi Iyer - April 26, 2017 | | See Original Here Taiwan Liposome Company, Ltd.,(TLC) (4152:TT) today announced that its oncology drug candidate TLC178 has been designated as a drug for a rare pediatric disease in the treatment of rhabdomyosarcoma…
Continue Reading »

Curing Cancer Is Within Reach

Curing Cancer Is Within Reach By Michael R. Bloomberg & Joe Biden | MARCH 30, 2016 | Bloomberg View | See Original Here One of the most frightening words a patient can hear from a doctor is “cancer.” We know it from the experience of our families and friends, and the millions of Americans who hear it directly from…
Continue Reading »

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable By ELIE DOLGIN | STAT News | DECEMBER 23, 2015 | See Original Here Cancer treatment is like an arms race. After a tumor evolves resistance to one drug, doctors switch to another therapeutic weapon — and on and on, until the tumor is vanquished or the…
Continue Reading »

It’s time for Congress to reinvest in cancer research

It’s time for Congress to reinvest in cancer research By Julie M. Vose, MD, MBA | The Hill | November 27, 2015 | See Original Here Research funded by the National Institutes of Health (NIH) is the basis for the most important cancer breakthroughs of our time, but it is threatened by more than a…
Continue Reading »

Metastatic Rhabdomyosarcoma: Still Room for Improvement

Metastatic Rhabdomyosarcoma: Still Room for Improvement Leonard H. Wexler | © 2015 by American Society of Clinical Oncology | See Original Here Author Affiliations: Memorial Sloan Kettering Cancer Center, New York, NY Of the approximately 400 children and adolescents diagnosed each year in the United States with rhabdomyosarcoma, between one in five and one in…
Continue Reading »

An Incredible Gift

The Game of Battleship and the Battle Against Rare Pediatric Cancers Alan R. Ehrlich, Chair, Focus on Rhabdo The game Battleship has been around for almost a century, starting off as a simple, two-player paper and pencil game requiring nothing more than each player drawing a 10x10 grid on piece of paper and positioning their…
Continue Reading »

Clear Surgical Margins Webinar – Dr. Andrea Hayes-Jordan

I want to thank Dr. Hayes-Jordan for an excellent and informative webinar on Clear Surgical Margins and the HIPEC procedure (22 June 2014).  I will be posting the video of the program in a few days (we experienced some technical difficulties that needs to be edited out). You can access the video of this webinar by…
Continue Reading »

Seneca Valley Virus Study – What Can We Do?

From Joan (reposted from the comments area) Imagine that there was an anti-cancer agent that had the all-time best response against rhabdomyosarcoma, particularly alveolar rhabdo, of ANY single agent EVER tested in the Pediatric Preclinical Testing Program. Imagine that all four alveolar rhabdo cell lines tested obtained a complete response in mouse xenografts. Imagine that…
Continue Reading »

Is it my imagination or are we seeing more Rhabdo cases in ‘older’ individuals?

We all know that Rhabdomyosarcoma is classified as a childhood cancer. It seems to me that we have been hearing more and more about cases of Rhabdo in older - teens and young adults - individuals. Most treatment protocols are based on childhood cases and provided in the children's area of the hospital. Is this…
Continue Reading »
12
Skip to toolbar